Luminex CEO Patrick Balthrop said this week that the company is "well into the alpha stage" of development for its high-volume, low-multiplex, cartridge-based clinical diagnostic system, dubbed Project Aries.

As such, Luminex's R&D spend increased by approximately 26 percent in the first quarter, a trend that it sees continuing over the next several quarters — though at a slightly slower pace — as it prepares the sample-to-answer testing platform for beta testing and possible commercialization next year, Balthrop said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.